Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

TAKEDA PHARMACEUTICALS AMERICA, INC.

UEI: DDEVYUAXJ624CAGE: 4DE70

TAKEDA PHARMACEUTICALS AMERICA, INC. is a federal contractor, registered under UEI DDEVYUAXJ624 and CAGE code 4DE70. It has been awarded $10,510,736 in federal contracts. Primary work spans Pharmaceutical Preparation Manufacturing and Other NAICS codes (2 codes, <0.5% each). Top awarding agencies include Department Of Justice, Department Of Veterans Affairs, and Department Of Defense.

Contact Information

Registration and classification details

Registration

UEI Code

DDEVYUAXJ624

CAGE Code

4DE70

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationForeign OwnedManufacturer of Goods

NAICS Codes

325412Pharmaceutical Preparation Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Takeda Pharmaceuticals America Inc. specializes in the manufacturing and supply of complex pharmaceutical preparations for federal agencies, with deep expertise in producing branded biologics and specialty therapeutics under strict cGMP standards. Their core capabilities include the end-to-end produ...

Takeda Pharmaceuticals America Inc. specializes in the manufacturing and supply of complex pharmaceutical preparations for federal agencies, with deep expertise in producing branded biologics and specialty therapeutics under strict cGMP standards. Their core capabilities include the end-to-end production of injectables, oral tablets, and bulk active pharmaceutical ingredients for niche indications, including rare disease treatments and immunotherapies. The company demonstrates advanced competency in managing multi-product supply chains, ensuring consistent quality across high-compliance environments, and maintaining secure, traceable distribution channels for controlled medications. Their technical focus centers on sterile manufacturing, lyophilization, and cold-chain logistics for temperature-sensitive biologics, with proven ability to support urgent, high-volume government demand cycles. The contractor maintains sustained relationships with the Department of Veterans Affairs and the Department of Justice, primarily supplying specialty pharmaceuticals to federal healthcare and correctional pharmacy systems. For the VA, they deliver critical therapies for hematologic, metabolic, and rare immune disorders, often through long-term blanket purchase agreements that ensure uninterrupted access to life-sustaining medications. The Department of Justice contracts reflect consistent provision of medications for federal detention and correctional facilities, indicating reliable compliance with federal formulary and controlled substance regulations. Their primary NAICS classification, 325412, reflects active pharmaceutical manufacturing of finished dosage forms, positioning them as a key supplier in the federal specialty drug market. They focus on high-complexity, low-volume therapeutics that require stringent regulatory oversight, distinguishing them from general pharmaceutical distributors. Takeda Pharmaceuticals America Inc. is a corporate entity headquartered in Lexington, Massachusetts, operating as a wholly owned subsidiary within a global pharmaceutical structure. The company holds no specific government certifications but leverages its FDA-registered manufacturing facilities and established quality systems to meet federal procurement requirements. Their geographic presence is centered in the Northeast biopharma corridor, with operations calibrated to support national government supply chain needs.

Key Performance Metrics

Awards Count

141

All time

Active

4

Currently performing

Completed

137

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
325412 - Pharmaceutical Preparation Manufacturing$10.5M99.7%
Others - Other NAICS codes (2 codes, <0.5% each)$30.1K0.3%
Awards by Agency Over Time
Awards by Place of Performance

Compete with TAKEDA PHARMACEUTICALS AMERICA, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for TAKEDA PHARMACEUTICALS AMERICA, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in TAKEDA PHARMACEUTICALS AMERICA, INC.'s top NAICS codes and agencies

NAICS: 325412
New
Federal
6505--Sacubitril/Valsartan Tablets (VA-27-00014055)
Solicitation # 36E79727R0007
The Department of Veterans Affairs Enterprise Procurement Office intends to award a single, unrestricted national mandatory requirements contract for an uninterrupted source of supply of Sacubitril-Valsartan Tablets. This procurement, issued under NAICS code 325412 and FAR Part 12, supports multiple federal entities, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers. The contract will span a one-year base period with four pre-priced one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs, requiring the contractor to execute necessary chargeback agreements to ensure timely delivery. The successful offeror must provide a unique eleven-digit National Drug Code (NDC) where the first five digits identify the offeror, and this must be the only label on the product. Strict packaging specifications are required for 60 and 180 count bottles, including a minimum volume of 120cc, a cylindrical body with at least a 5.75 inch circumference, and a safety cap that is either convertible or deshellable. Bottles must accommodate a 5.25 by 2 inch label with an additional 0.5 inch of space for barcodes and expiration data. Offerors who are not the manufacturer must provide a letter of commitment ensuring a sufficient source of supply. The solicitation is expected to be issued around December 18, 2026, with a tentative closing date of January 7, 2027.
Nac Pharmaceuticals (36E797)

POSTED

about 7 hours ago

DEADLINE

in 12 days
View Details
NAICS: 325412
New
DIBBS
BUPIVACAINE AND EPINEP
Solicitation # SPE2DP-27-T-0139
Solicitation SPE2DP-27-T-0139, issued by the DLA Troop Support Medical Supply Chain Pharm FSA, is for the procurement of Bupivacaine and Epinephrine Injection. The specific requirement is for 0.500 PCT W/V Bupivacaine HCl and 0.005 mg Epinephrine/mL (1:200,000) provided in 1.8 mL cartridges, with a total quantity of one can containing 50 units. The product must be stored at a controlled room temperature between 15 and 30 degrees Celsius and has a total shelf life of 18 months, with at least 15 months remaining upon delivery to the first government activity. Delivery is required within 20 days after receipt of order, with a required delivery date of October 23, 2026, destined for the USS TUCSON SSN 770. The contract mandates strict adherence to Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must be commercial, utilizing sealed unit containers and exterior shipping containers, with palletization following DLA packaging requirement RP001. Inspection and acceptance are conducted at the destination per FAR 52.246-2. Invoicing and payment must be processed electronically through the Wide Area WorkFlow system. The procurement is governed by NAICS code 325412 and includes various FAR and DFARS clauses covering hazardous material identification, cybersecurity safeguarding of covered defense information, and domestic material restrictions under the Buy American Act.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details